Novel research clarifies the effects of long-term schizophrenia medication on cognitive function.
Researchers from Japan have revealed a new neural pathway that links stress with organ dysfunction.
This article discusses two potential neural networks, the serotonergic system and the OTergic system, that could prove to be particularly useful targets for endocrine therapy.
Megan Zuelsdorff discusses her research into the impact of lifetime stressful experiences on cognition as part of the Wisconsin Registry for Alzheimer’s Prevention Study.
This study generates a novel dataset of associations for disorders such as major depression and schizophrenia, providing a global perspective for their genetic etiology.
The hypothesis that antidepressant response has a relevant genetic component was initially suggested by the observation that this phenotype clusters in families.
How effective are non-invasive brain stimulation techniques on the symptoms of psychiatric disorders? How far has the field come, and what’s next?
This study aimed to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
This review explores promising novel genetic variants derived from preclinical models of alcohol consumption and dependence, and identifies novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.
In this perspective article, the authors draw attention toward the pharmacoepigenomic influence of antipsychotic drugs, and distinguish its significance from therapeutic response and schizophrenia pathogenesis.